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CRC Colorectal cancer  
 
Ca 19-9 Cancer antigen 19-9 
 
CEA Carcino-embryonic antigen 
 
gFOBT Guaiac faecal occult blood test  
 
IALCH Inkosi Albert Luthuli Central Hospital  
 
SA South Africa 
 
S- CEA Serum levels of Carcino-embryonic antigen 
 
TPA Tissue plasminogen activator  
 








Table 1 CEA Level µg/l based on race, age and gender 
 
Table 2 Contingency of CEA level (µg/l) in gender, age and race 
 






















Figure 1 Correlation between the level of CEA (µg/l) and age (r
2
 = 0.008; p = 
0.008). Mean CEA levels declined as age increased  
 
Figure 2 Correlation between the level of CEA (µg/l) and the stage of CRC (r
2
 = 
0.054; p < 0.0001). An elevated CEA level is associated with a higher 
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OVERVIEW OF THESIS 
 
Colorectal cancer (CRC) is the third most common malignancy in the world with the global 
incidence of CRC projected to rise up to 60% by 2030. More than one million new cases are 
diagnosed per annum and 530 000 deaths are reported per year worldwide. Importantly the 
slow growth of CRC warrants early screening to reduce both the incidence and mortality of 
the disease. Screening should be to primarily detect CRC at a relatively early stage (stage 1 
and 2). However, currently the most reliable diagnostic tool, colonoscopy, is not readily 
accessible in the resource deprived setting of KwaZulu-Natal, South Africa. 
 
Carcinoembryonic antigen (CEA) is one of the most widely used tumour markers worldwide. 
It was first described in 1965 by Gold and Freedman. CEA is a glycoprotein with a molecular 
weight of 200 000 Daltons. It was initially identified and immunolocalized on both foetal 
colon and colon adenocarcinoma. CEA is also present in normal tissue at ≤3 ng/ml, which is a 
60-fold lower concentration than in malignant tissue. Data on the role of CEA as a prognostic 
marker for CRC in sub-Saharan Africa is limited. 
 
KwaZulu-Natal is a province of South Africa, with an estimated population of 12 million. 
Despite this large population, only 8 medical facilities offer colonoscopy to the public health 
care sector, with resultant huge delays in acquiring screening or diagnostic colonoscopies in 
this resource-deprived setting. CRC is the fourth most common cancer in South Africa (SA). 
xi 
 
Given that there is currently no reliable tumour marker available for this pathology, coupled 
with a background of limited availability of diagnostic measures like colonoscopy, the value 
of CEA as a tumour marker for CRC in this resource-deprived setting should be further 
explored. It was therefore the aim of this study to determine whether serum CEA level in 
patients symptomatic for lower GI pathology correlates with the histological presence and 
severity of primary colorectal cancer in a large referral centre within KwaZulu-Natal and 
further, to explore the possibility of using the CEA level to fast-track patients to colonoscopy. 
 
We present a retrospective analysis of prospectively collected clinical data investigating the 
demographic data, stage of CRC, and CEA level prior to chemotherapy, radiotherapy and/or 
definitive surgery. We conducted a retrospective case study on 380 patients who attended the 
Colorectal Clinic at the tertiary referral hospital, Inkosi Albert Luthuli Central Hospital, 
Durban, South Africa during the period of 2007-2016. Variables collected included race, age, 
and gender, pre-treatment CEA, and stage of CRC. GraphPad Prism 5.00 for Windows 
(GraphPad Software, San Diego, California, USA) was used for data analysis. 
 
Similarities and differences between our findings and currently known data were observed. 
Despite the proposal of CEA as a tumour marker for CRC, we confirm its low sensitivity as a 
screening test for CRC. Moreover, in light of the poor access and long delays associated with 
colonoscopy in the public health care sector of South Africa, it is urgent that patients with 
suspected CRC are speedily evaluated via non-invasive techniques. We wondered if, in 
resource-poor settings, an elevated serum CEA could also serve as a test that serves as a 
xii 
 
trigger for clinicians to perform colonoscopy in order to diagnose CRC. However, CEA has 
no diagnostic role due to its low sensitivity and specificity to CRC, and we have not shown 
any benefit of CEA levels as a risk assessment tool to be used to fast-track symptomatic 
patients for colonoscopy. We recommend therefore that less invasive approaches be promoted 
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BACKGROUND AND LITERATURE REVIEW 
 
1.1 Introduction 
Carcinoembryonic antigen (CEA) is one of the most widely used tumour markers worldwide. It 
was first described in 1965 by Gold and Freedman
1, 2
. Carcinoembryonic antigen was initially 
identified and immunolocalized on both healthy foetal colon and adenocarcinoma of the colon, 
but it is absent from healthy adult colon 
2
. The term “carcinoembryonic antigen” was coined 
because it was initially only identified in cancer and embryonic colon. 
The CEA molecule is an onco-developmental human tumour marker and bears the cluster 
differentiation designation, CD66
3
. It is a membrane surface glycoprotein that interacts with the 
microskeleton of the cell 
4, 5
. Carcinoembryonic antigen is released from the cell surface, into the 
interstitial space from where it enters into the general circulation 
6
.  
Colorectal cancer (CRC) is the third most common malignancy in the world 
7
. More than one 
million new cases are diagnosed per annum, and 530 000 deaths are reported per year 
7
. The  
slow growth of CRC warrants early screening as early identification would enable better 
management. A good biomarker for  early identification of  CRC has the potential to reduce both 
the incidence and mortality of the disease. However, currently the most reliable screening tool, 
colonoscopy, is not readily accessible  in resource-deprived settings. 
Kwa-Zulu Natal is a province of South Africa, with an estimated population of 12 million. 
Despite its large population, only 8 centres offer colonoscopy in the public health care sector, 
resulting in huge delays in acquiring screening/diagnostic colonoscopies. Perhaps CEA may have 
a larger role as a risk assessment tool for CRC development in these communities. Nonetheless, 
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the use of using CEA as a  risk assessment tool to guide diagnostic investigation in symptomatic 
patients has limitations.    
 
1.1 Factors affecting serum CEA levels in patients with CRC include: 
 Tumour Stage: CEA levels are elevated with increased disease stage. This was shown in 
an early study in which the proportion of patients with increased CEA concentration 
(>5ug/l) were as follows: Dukes A disease 3%; Dukes B disease 25%; Dukes C disease 
45%; and Dukes D disease 65% 
8
. 
 Tumour Grade: Several studies have shown that well differentiated CRC’s produce more 
CEA per gram of total protein than poorly differentiated tumours 
9, 10
. Consequently, S-
CEA tends to be higher in patients with well-differentiated tumours compared with those 
poorly differentiated tumours. This counter-intuitive finding may explain why some 
patients with advanced CRC do not have increased S-CEA values.  
 Liver Status: The liver is the primary site of metabolism of CEA11 . Carcinoembryonic 
antigen is initially taken up by the Kupffer cells, and modified by removing its sialic acid 
residues 
12
. Thereafter, it is endocytosed by liver parenchymal cells, where it undergoes 
degradation. Therefore, in conditions where the liver function is impaired such as in 
certain benign liver diseases, serum CEA levels are elevated 
12
. 
 Tumour Site: CRC’s located at the left colon generally have increased CEA levels 
compared to those located on the right 
8, 13
. 
 Smoking increases the CEA value by a factor of two in both males and females 14. 
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1.2 CEA as a marker for CRC 
1.2.1 Screening 
The World Health Organisation defines screening as the presumptive identification of 
unrecognized disease in an apparently healthy, asymptomatic population by means of tests, 
examinations or other procedures that can be applied rapidly and easily to the target population
15
, 





non-specific presentation of an early stage CRC makes clinical detection difficult. The aim of 
screening should be to detect the disease in asymptomatic patients at a relatively early stage 
(Dukes A or B). CEA concentrations are, in general, more often raised in smokers than in non-
smokers, and more frequently elevated in men than in woman 
14
. Fletcher et al  calculated that 
CEA has a sensitivity of 36% and specificity of 87% in screening for Dukes stages A or B 
(Appendix 5) in CRC
 16
. The same study used an upper limit of normal for CEA (2.5ug/l) which 
rendered the positive predictive value of CEA to be unacceptably low and thus of little value as a 
screening test for CRC. This is also in agreement with recommendations of the National 





Studies have demonstrated a  lack of sensitivity and specificity for CEA that limit its application 
in diagnosis, especially in early disease 
16
. With respect to CRC, although more than 80% of 
patients with advanced disease have elevated circulating CEA levels, the CEA assay alone 
should not be used as the sole diagnostic test for suspected cancer
19
. A sensitivity of 78% for 
Dukes stage B and 91% for Dukes stage C has been achieved using CEA levels in combination 
with Ca19-9 and tissue plasminogen activator (TPA) levels 
20
. Regarding the specificity of CEA 
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in CRC, it must noted that CEA is increased in most types of advanced adenocarcinomas as well 




1.2.3 Assessing Prognosis 
Multiple studies report that patients with high pre-operative levels of CEA have a worse 
prognosis than those with lower levels 
21-22
. Several studies have investigated the prognostic 
impact of CEA in Dukes A or B disease and found that high pre-operative CEA levels correlate 
with poorer prognosis
 23-28
. In another study, although CEA alone was not independently 
prognostic, when combined with CA 242, the elevation of both markers indicated a poorer 
prognosis in this group of patients
26
. The forgoing studies are producing conflicting results 
suggesting that CEA has limited use as a prognostic marker in CRC. 
The post-operative use of CEA may also have prognostic value. Evidence suggests that high 
post-operative levels may also predict adverse outcome 
29
. After an oncological resection of a 
CRC, CEA levels return to normal values within 4-6 weeks
29
. Failure of the CEA level to return 




2.0 Problem Statement and Research question 
 
Colorectal cancer (CRC) is the fourth most common malignancy in the South Africa
30
.  The  
slow growth of CRC engenders a potential for earlier detection thereby potentially reducing both 
the incidence and mortality of the disease. However, currently the most reliable screening tool, 
colonoscopy, is not readily accessible in resource-deprived settings. 
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Due to the dire shortage of colonoscopy in KwaZulu-Natal, CEA may have value as a risk 
assessment tool for CRC development. However thus far, the role of CEA in screening and 
diagnosis remains unproven and its role on prognostication shows promise. 
 
Therefore, the overall impact of this study is to determine whether serum CEA levels in patients 
symptomatic for lower GI pathology correlates with the histological presence of primary CRC, 
stage of CRC and to identify any link to patients’ demographics. Also, we seek to determine 
whether CEA can be used as a surrogate biomarker to expedite colonoscopy and consequently 
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ABSTRACT 
Background: Colorectal cancer (CRC) is the fourth most common malignancy in South Africa. 
Currently the most reliable screening tool, colonoscopy, is not readily accessible in resource-
deprived settings of KwaZulu-Natal. The aim of this study was to determine whether serum CEA 
levels in patients symptomatic for lower GI pathology correlates with the histological presence 
and severity of primary colorectal cancer in a large referral centre within KwaZulu-Natal. 
Perhaps CEA may have a larger role as a marker for CRC development in these resource 
deprived communities. 
Patients and Methods: This study was a retrospective analysis of prospectively collected 
clinical data of 380 patients with colorectal cancer attending a tertiary referral centre in 
KwaZulu-Natal. Patients were of various age groups, various population groups and both 
genders. Serum levels of CEA were analysed and stratified into < 5 µg/l and ≥ 5 µg/l. Data were 
analyzed using descriptive statistics and findings were compared with those from the existing  
literature. 
Results:  CEA levels were studied in 380 consecutive patients with known pre-treatment CEA 
levels. The mean CEA level of the study population was 170.0 ± 623.3 µg/l.  The number of 
participants with a CEA level < 5µg/l was 151 (39.74%) whilst the majority 229 (60.26%) had a 
CEA level ≥ 5 µg/l. There was no significant correlation between CEA levels and gender (p=0.8) 
or age (p=0.6). CEA levels were highest in the Black African race group. Pairwise comparison 
demonstrated a statistically significant difference between the Black and Indian population 
groups (p=0.02). The current study demonstrates an upregulation of CEA as the stage of CRC 
progresses (p<0.0001).    
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Conclusion: There was no significant difference in CEA levels across age and gender. A 
positive correlation was noted between CEA level and stage of CRC. CEA levels were highest in 




















- 16 - 
 
INTRODUCTION 
Colorectal cancer (CRC) is the third most common malignancy in the world (1). The global 
incidence of CRC is projected to rise up to 60% by 2030 (2, 3). More than one million new cases 
are diagnosed per annum, and 530000 deaths are reported per year. CRC evolves 
across four distinct carcinogenic conduits: the chromosomal instability pathway (4), the 
microsatellite instability pathway (4), the Cytosine-Phosphate-Guanine(CpG) methylator 
pathway-1 (5) and pathway-2 (6). Importantly the slow growth of CRC warrants early screening 
to reduce both the incidence of and mortality from the disease. The aim of screening should be to 
detect CRC at a relatively early stage (stage 1 and 2). However, currently the most reliable 
diagnostic tool, namely colonoscopy is not easily accessible in resource-deprived settings. 
 
Carcinoembryonic antigen (CEA) is one of the most widely used tumour markers worldwide. It 
was first described in 1965 by Gold and Freedman (7, 8). CEA is a glycoprotein with a 
molecular weight of 200 000 (9). It was initially identified and immunolocalized on both fetal 
colon and colon adenocarcinoma (10). CEA has been found to be overexpressed in a wide 
variety of epithelial malignancies (11). The literature attributes the elevated CEA levels in CRC 
to tumour vascularity, necrosis, mitotic activity and differentiation (11). It is thus widely used 
clinically as both a blood and tissue tumour marker of epithelial malignancy, especially for 
tumours of the colon and rectum. CEA is also present in normal tissue at levels of ≤3 ng/ml, 
which is  60-fold lower concentration than that seen in malignant tissue (12).  
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Several studies have implicated high preoperative concentrations of CEA with adverse outcome 
in patients with Duke’s B colorectal cancer (13). More recently, Su et al. (14) demonstrated an 
overall sensitivity of CEA for the detection of CRC at 37.0%; however, they also found levels to 
be directly related to stage namely 21.4%, 38.9%, and 41.7% for stages I-III, respectively. These 
are unacceptably low predictive values, hence the need to rely on colonoscopy as a gold 
standard. Data on the role of CEA as a prognostic marker for CRC in sub-Saharan Africa are 
limited (15). 
 
KwaZulu-Natal is a province of South Africa, with an estimated population of 12 million. 
Despite this large population, only 8 medical facilities offer colonoscopy to the public health 
care sector, with resultant huge delays in acquiring screening or diagnostic colonoscopies in this 
resource-deprived setting. Currently, a reliable tumour marker for CRC is unavailable.  
 
In light of the fact that CRC is the fourth most common cancer in South Africa (SA) (16), the 
aim of this study was to determine whether serum CEA levels in patients symptomatic for lower 
GI pathology correlate with the histological presence and severity of primary colorectal cancer in 
a large referral centre within KwaZulu-Natal. Perhaps CEA may have a larger role as a risk 
assessment tool for the development of CRC in these resource-deprived communities. However 
thus far, the value of CEA in screening, diagnosis, and prognosis in KwaZulu-Natal remains to 
be accurately defined. 
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MATERIALS AND METHODS 
Study setting: This  study was carried out in the Colorectal Clinic at Inkosi Albert Luthuli 
Central Hospital,  the tertiary referral hospital in Durban, South Africa. 
Study Population: The study population (n=380) consisted of patients diagnosed with colorectal 
cancer who were extracted from the on-going colorectal cancer database which is archived in the 
Gastrointestinal Cancer Research Centre of the University of KwaZulu-Natal. Patients who were 
tested for baseline CEA form the basis of this analysis. They included Indian, Black African, 
White and Coloured patients, as described by the South African Government. CEA levels were 
compared  across various age groups and both genders with colorectal cancer. International 
Statistical Classification of Diseases and Related Health Problems (10th revision) (ICD-10) 
diagnosis codes were used to identify colorectal cancer. 
Study design: This was a retrospective analysis of prospectively collected clinical data of patients 
with known baseline CEA levels. Serum was collected from patients with confirmed colorectal 
cancer but who have not yet had resectional surgery. The period of study was 2007 to 2016. The 
serum was immediately analysed for CEA levels using the enzyme-linked immunosorbent assay 
(method). A serum CEA >5 µg/l was considered elevated. 
Colonoscopy was performed by gastroenterologists using an Olympus Medical Systems, Tokyo, 
Japan colonoscope. All participants received four litres of polyethylene glycol solution for bowel 
preparation. Biopsies were obtained and evaluated by state pathologists via histopathological 
examination. TNM and UICC staging (Appendix 6) are used in the colorectal cancer database. 
For the purpose of this paper UICC staging was used. The inclusion criteria for the study 
comprised patients with histologically confirmed colorectal cancer and staging.  
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Demographics, site of primary tumour, presence of metastatic disease and CEA level prior to 
chemotherapy, radiotherapy and/or definitive surgery were collated into a datasheet for statistical 
analysis. 
Ethical considerations 
This retrospective clinical study received institutional ethics approval (BE016/17). Additionally, 
approval was obtained from the National Department of Health and the Hospital manager.   
Statistical Analysis 
Nonparametric data are represented as median and interquartile range (IQR). GraphPad Prism 
5.00 for Windows (GraphPad Software, San Diego, California, USA) was used for data analysis. 
The Fisher’s Exact/Chi Square test was used for analysis. To determine statistical significance 
across all study groups a Kruskal-Wallis (Dunn’s multiple comparison) or a Mann-Whitney U 
test was carried out. Spearman coefficients were used to correlate CEA levels with the patient 
demographic as well as the stage of CRC.  A p value of < 0.05 was considered as statistically 
significant.   
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RESULTS 
There was a total of 380 patients with colorectal cancer including 46 (12.11%) younger 
presenters (age < 40 years) and  334 (87.89%) older presenters (age < 40 years). The study 
population (n=380) consisted of Indian (47.6%), Black African (34.5%), White (14.7%) and 
Coloured (3.2%) patients with a histologically confirmed colorectal cancer. Two hundred and 
twelve (55.8%) participants were males and 168 (44.2%) were female (Male: Female ratio = 1: 
0.79). The mean age of the study population was 57.7 ± 13.6 years.  
 
CEA levels were stratified into < 5 µg/l and ≥ 5 µg/l and is outlined in Table 1. The mean CEA 
level of the study population was 170.0 ± 623.3 µg/l.  The number of participants with a CEA 
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Table 1: CEA Level µg/l based on race, age and gender 
 
 Sample size (n) CEA level* p value 
Race 




Black African 131 232.0 ± 742.9 
Coloured 12 98.98 ± 349.7 
White 56 39.66 ± 104.8 
Age 
< 40 Years 46 266.7 ± 736.3 
p= 0.60 
> 40 Years 334 157.5 ± 607.5 
Gender 
Female 168 219.2 ± 779.0 
p= 0.80 
Male 212 131.1 ± 462.7 
 
Legend 
*  CEA level in Mean + Standard deviation 
#  Pairwise comparisons of each race groups vs another one, as well as Black African vs all others (Mann-
Whitney Test): 
   Between all 4 races   p=0.08 
    Black African vs Indian        p=0.04  
Black African vs Coloured  p=0.06 
Black African vs White   p=0.13 
Black African vs all others   p=0.02 
Indian vs Coloured   p=0.23 
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CEA levels were evaluated across the study population and there was no significant difference 
between a CEA level ≥ 5 µg/l and gender (Kruskal-Wallis H = 272.8; p = 0.8; Table 1). CEA 
levels were higher in females (219.2 ± 77.9 µg/l) compared to males (131.1± 462.7 µg/l). 
However, this did not reach statistical significance. 
 
CEA levels were highest in Black African patients (232.0 ± 742.9 µg/l) compared to other 
population groups (Table 1). The difference across the population groups did not reach statistical 
significance (p=0.08). However, pairwise comparison demonstrated a statistically significant 
difference between the Black African and Indian population groups (p=0.04). The  difference in 
the CEA levels between the Black African group on the one hand and the other population 
groups combined on the other, was also statistically significant (p=0.02). 
 
As shown in Figure 1, mean CEA levels declined with increasing age (p= 0.008). There was no 
significant difference in CEA levels between young presenters (age < 40 years) and older 
presenters (age > 40years) (p = 0.87). This is well demonstrated in Table 2. Additionally, as the 
severity of CRC increased, CEA levels increased significantly across all age groups (Figure 2). 
Table 3 shows the staging in study patients. As  shown in Figure 2,  an elevated CEA level is 
associated with a higher stage of CRC (r
2
 = 0.054; p < 0.0001). The odds ratio of having a CEA 
level ≥5µg in stage 4 CRC was 11.28 (CI=4.51 – 28.18; p<0.0001).  
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Figure 1: Correlation between the level of CEA (µg/l) and age (r
2
 = 0.008; p = 0.008). Mean 
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Male (n = 212) Female (168) Fisher’s Exact Test 
 N % N % 
p = 0.75 < 5 86 40.56 65 38.69 




< 40 years (n=46) > 40 years (n=334) Fisher’s Exact Test 
 N % N % 
p = 0.87 < 5 18 39.13 135 40.42  





(n = 181) 
Black African 
(n = 131) 
White 
(n = 56) 
Coloured 
(n = 12) 
Chi Square Test 
 N % n % n % N % 
X
2
 = 2.90,3 
p = 0.40 
<5 75 41.44 45 34.35 25 44.64 6 50 
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Table 3: Staging in 380 patients with Colorectal Cancer and known preoperative CEA 
levels 
 
Stage n % 
Stage I 24 9 
Stage II 59 15.5 
Stage III 58 15.3 
Stage IV  143 37.6 
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Figure 2: Correlation between the level of CEA (µg/l) and the stage of CRC (r
2
 = 0.054; p < 
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DISCUSSION 
The current study demonstrates an upregulation of CEA as the stage of CRC progresses. 
Whereas age is an established risk factor for the development of CRC (17), we report in this 
study that there was no significant difference between the CEA levels and age. This is supported 
by a large Korean study, which showed serum CEA to be a vital risk factor for the development 
of advanced colorectal neoplasms in both young (< 50 years) and old adults (≥ 50 years) (17).  
 
Internationally the incidence of CRC is reportedly higher in men than in women and strongly 
increases with age (18). In South Africa, the cumulative lifetime risk of developing CRC 
amongst all race groups is  reported at 1.24 for males and 0.74 for females (16). This series 
demonstrated no significant difference in the CEA levels between males and female genders.  
 
In the past, colorectal cancer was reported to be an uncommon disease in South African Blacks 
(20). Westernization of the rural Black African population of South Africa has resulted in an 
increase in dietary animal fat and protein (meat) intake (21), which are established risk factors 
for the development of CRC (22) and may explain the observed increase in the diagnosis of 
colorectal cancer among Black African patients. This study has shown that CEA levels were 
highest in Black African patients compared to other race groups. While it is tempting to postulate 
that this is related to the later stage at presentation of the disease in the Black African race group 
this needs to be validated by  further research. 
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The current  study reports a significant positive correlation between baseline CEA levels and the 
stage of CRC. The clinical implication of this finding is that CEA levels may be used as a 
prognostic marker for stage IV CRC although it does not appear to be a good marker for stage 
I,II and III disease. However, the clinical use of CEA as a prognostic marker for stage IV CRC is 
limited as management at this stage of disease would largely be palliative. These findings are 
corroborated by the findings of Kim et al which demonstrated that elevated CEA levels 
correlated well with  advanced stages of CRC and a poorer clinical outcomes (17). 
 
Zhang et al have previously postulated that the combined detection of serum CEA and CA 19-9 
could play a complementary role in the diagnosis of CRC, and could significantly improve the 
sensitivity for the diagnosis of CRC (23). CA 19-9 might be a tumour biomarker in addition to 
CEA for CRC (23). Despite this proposal, we demonstrated in this series that only 60.26% of 
patients with confirmed CRC had an elevated CEA level. Other authors have also shown a very 
low sensitivity of this test and concluded that there is no role for CEA assessment as a screening 
tool for CRC (24). We concede that CEA has no diagnostic role due to its low sensitivity and 
specificity to CRC. Therefore, in light of the poor access and long delays associated with 
colonoscopy in the public health care sector of South Africa (25), it is crucial that one is able to 
better evaluate patients with suspected CRC via non-invasive techniques such as the stool guaiac 
occult blood test.  
 
Limitations of the present study include a lack of quantitative stratification of groups into 
smoking and non-smoking sub-groups bearing in mind that CEA concentrations are affected by a 
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variety of factors including smoking and gender (26). Also, comparison of the White or Coloured 
race groups was not statistically significant due to the small sample sizes of these groups 
respectively. Furthermore a potential bias of the sampling technique is that this study only 
included patients who had a pre-operative level of CEA. Also, patients are often referred to the 
Colorectal unit after surgical resection with pre-cluded their inclusion in this study. 
 
In conclusion this study reports no significant difference in CEA levels across age or gender.  
The CEA levels were found to be highest in the Black African race group and  the present series 
confirms a low sensitivity of CEA as a diagnostic test for CRC. Finaly, this study does identify 
that CEA levels are higher with increased stage of CRC. The clinical implication of this finding 
is that CEA levels may be be a reasonably good marker for stage IV CRC although it has failed 
to demonstrate reliability as a risk assessment tool for stage I, II and III disease. Having said this, 
we concede that  the clinical use of CEA as a marker even  for stage IV CRC remains  limited as 
management of this stage of disease would largely be palliative. We have therefore not shown 
the benefit of CEA levels as a risk assessment tool to be used to fast-track symptomatic patients 
for colonoscopy. For now it is worth exploring the possibility of fast-tracking patients with high CEA 
to radiological investigations, and, if extensive metastatic disease is found, then a possibility of 
colorectal cancer can be entertained and thus the need for urgent diagnostic colonoscopy avoided. 
We further recommend that less invasive approaches be promoted in resource-limited settings 
including the use of Guaiac faecal occult blood test (gFOBT). 
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Special attention to improve colorectal cancer screening in African countries are necessary to 
improve survival rates. Finally, the role of hereditary colon cancer in young Black Africans and 
its impact on survival remains largely unexplored. 
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Title of Study: THE ROLE OF CARCINOEMBRYONIC ANTIGEN IN PREDICTING 
COLORECTAL CANCER IN RESOURCE POOR SETTING OF KWAZULU-NATAL, 
SOUTH AFRICA 
 
Primary Investigator: Dr YD Naicker, Department of Surgery, Nelson R. Mandela School of 
Medicine, University of KwaZulu-Natal. 
 
Supervisor: Prof TE Madiba (Department of Surgery; Colorectal Surgery, IALCH) 
Co-Supervisor: Dr Z Moolla (Department of Surgey; Fellow at Colorectal Surgery, IALCH) 
 
1. ACRONYMS AND ABBREVATIONS 
 
CEA: Carcinoembryonic enzyme assay 
CRC: Colo-rectal cancer  
Ca 19-9: Cancer antigen 19-9 
TPA: Tissue plasminogen activator 
IALCH: Inkosi Albert Luthuli Central Hospital 
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2. BACKGROUND AND PURPOSE OF STUDY 
 
3. AIMS OF THE STUDY 
Primary Aim 
The aim of this study is to determine whether serum CEA level in patients symptomatic for 
lower GI pathology correlates with the histological presence of primary CRC. 
Secondary Aim 
 To correlate CEA levels with patient demographics 
 To correlate CEA levels with stage of CRC 
 
Specific objectives of study 
 Can CEA be used as a surrogate biomarker to expedite colonoscopy and confirmation of 
a colorectal cancer in resource poor settings (where there is a shortage of endoscopists 
and long queues for colonoscopy). 
 
4. LITERATURE REVIEW 
4.0 Introduction 
Carcinoembryonic antigen (CEA) is one of the most widely used tumour markers worldwide. It 
was first described in 1965 by Gold and Freedman
1, 2
. It was initially identified and 
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immunolocalized on both fetal colon and colon adenocarcinoma, but is absent from healthy adult 
colon 
2
. The term CEA was coined because it was only identified in cancer and embryonic colon 
at the time. 
The CEA molecule is an onco-developmental human tumour marker and bears the cluster 
differentiation designation, CD66
3
. It is a membrane surface glycoprotein immunoglobulin that 
interacts with the microskeleton of the cell 
4, 5
. It is released from the cell surface, into the 
interstitial space and thereby enters into the general circulation
6
.  
Colorectal cancer (CRC) is the third most common malignancy in the world.   More than one 
million new cases are diagnosed per annum, and 530000 deaths are reported per year 
7
. It‘s slow 
growth means that early screening for CRC has the potential to reduce both the incidence and 
mortality of the disease. However, currently the most reliable screening tool, colonoscopy, lacks 
access in resource deprived settings. 
 Kwa-Zulu Natal is a province of South Africa, with an estimated population of 12 million. 
Despite its large population, only 8 centres offer colonoscopy in the public health care sector, 
resulting in huge delays in acquiring screening/diagnostic colonoscopies. Perhaps CEA may have 
a larger role as a risk assessment tool for CRC development in these communities. Thus far the 
role of CEA in screening, diagnosis, and prognostication remains to be adequately defined. 
Nonetheless, the use of using CEA as a  risk assessment tool (to guide diagnostic investigation) 
in symptomatic patients has limitations.   
4.1 Factors affecting serum CEA levels in patients with CR include: 
 Tumour Stage: CEA levels are elevated with increased disease stage. This was shown in 
an early study in which the proportion of patients with increased CEA concentrations 
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(>5ug/l) were as follows: Dukes A disease 3%; Dukes B disease 25%; Dukes C disease 
45%; and Dukes D disease 65% 
8
. 
 Tumour Grade: Several studies have shown that well differentiated CRC’s produce more 
CEA per gram of total protein than poorly differentiated tumours 
9, 10
. 
 Liver Status: The liver is the primary site of metabolism of CEA. It is initially taken up 
by the kupffer cells, and modified. Thereafter, it is endocytosed by liver parenchymal 
cells, where undergoes degradation. Therefore, in conditions where the liver function is 
impaired such as in certain benign liver diseases, serum CEA levels are increased 
11
. 
 Tumour Site: CRC’s located at the left colon generally have increased CEA levels 
compared to those located on the right 
8, 12
. 
 Smoking increases the CEA value by a factor of two in both males and females 13. 
 
4.2 CEA as a marker for CRC 
4.2.1 Screening 
The non-specific presentation of an early stage CRC makes clinical detection difficult. 
Therefore, the aim of screening should be to detect the disease at a relatively early stage (Dukes 
A or B). CEA concentrations are, in general, more often raised in smokers than in non-smokers, 
and more frequently elevated in men than in woman 
13
. Fletcher et al (1986) calculated that CEA 
has a sensitivity of 36% and specificity of 87% in screening for Dukes stages (A or B) in CRC. 
The latter study used an upper limit of normal for CEA (2.5ug/l) 
14
 which rendered the positive 
predictive value of CEA to be unacceptably low and thus of little value as a screening test for 
CRC (defined as procedures for detection of disease in asymptomatic individuals). These results 
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were corroborated by data from a large cohort, population based Framingham et al study, which 
examined CEA levels in serum samples from patients with newly detected CRC
15
.  This is also 
in agreement with recommendations of the National Institution of Health Consensus 





The lack of sensitivity and specificity limit the application of CEA in diagnosis, especially in 
early disease 
14
. With respect to CRC, although >80% of patients with advanced disease have 
circulating CEA, the CEA assay alone should not be used as the sole diagnostic test for 
suspected cancer
17
. Regarding the specificity of CEA in CRC, it must be remembered that CEA 
is increased in most types of advanced adenocarcinomas as well as multiple benign disorders 
17
. 
More recently, the antigen antibody reactions targeting CEA alone or in combination with other 
tumour markers, show higher sensitivities in the diagnosis of CRC. A sensitivity of 78% for 
Dukes stage B and 91% for Dukes stage C has been achieved using this technology in 




4.2.3 Assessing Prognosis 
Multiple studies report that patients with high pre-operative levels of CEA have a worse 
prognostic outcome than those with lower levels 
19-20
. Several studies have investigated the 
prognostic impact of CEA in Dukes A or B disease 
21-26
. A predominance of studies report that 
high CEA levels can predict adverse outcome. However, in a study examining only a subset of 
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Dukes B stage, the predictor indictor value of CEA was negative
 22
. In a similar study, although 
CEA alone was not prognostic in Dukes B patients, when combined with CA 242, the two 
markers together yielded significant prognostic information in this subgroup of patients
24
. 
Therefore, preoperative serum CEA levels can provide prognostic data in patients with Dukes A 
or B CRC. Carcinoembryonic antigen may thus be able to help identify the subset of patients 
with early CRC with aggressive disease who may benefit from adjuvant chemotherapy. There is 
however, currently no evidence to show the benefit of adjuvant chemotherapy based solely on 
pre-operative CEA levels. 
The post-operative use of CEA may also have prognostic value. Evidence suggests that high 
post-operative levels may also predict adverse outcome 
27
. After an oncological resection of a 
CRC, CEA levels returns to normal values within 4-6 weeks. Failure of the CEA to return to 
normal within 6 weeks post resection is frequently associated with early recurrent disease
27
.  
In light of the value of CEA as a screening tool for CRC, this study aims to determine whether 
serum CEA level correlates with the histological presence of primary CRC. 
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5. STUDY SETTING 
Inkosi Albert Luthuli Central Hospital (IALCH) -Colorectal clinic 
 
6. STUDY DESIGN 
Retrospective review of prospectively collected data 
 
7. STUDY POPULATION 
The study population consisted of patients referred to IALCH colorectal clinic between the 
period 2007-2013.   
 Inclusion Criteria: histologically confirmed presence of all stages of CRC 
 Exclusion criteria: absence of CRC 
 
8. SAMPLE SIZE 
Consulted institutional biostatistician. 
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9. SAMPLE COLLECTION 
Blood was collected at venepuncture from patients attending the IALCH colorectal clinic 
between the period 2007-2013, a large central referral hospital in Durban, KwaZulu-Natal, South 
Africa. 
 
10. STUDY PERIOD 
Serum was collected from patients during the period 2007-2013. 
 
11. METHODS AND TOOLS 
Patient demographics, date of diagnosis and pre-treatment CEA values will be analysed. 
Demographics will include age, sex, race, site of primary tumour, presence of metastatic disease, 
CEA level prior chemotherapy/Radio-therapy or definitive surgery.  
Serum CEA levels was analysed using the enzyme linked immunosorbent assay that identified 
CEA. A serum CEA >5ng/ml will be considered increased. 
 
12. STATISTICAL ANALYSIS:  
All statistical analysis was undertaken using GraphPad Prism version 5 (GraphPad software 
version 5, San Diego, Califonia, USA). To analyse non-normal data, we used non-parametric t-
test (Mann-Whitney U). Spearman coefficients were used to evaluate correlations between 
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biomarkers. A p value of <0.05 was considered as statistically significant. Graphical data 
represented as median and interquartile range. BREC approved data-base study. 
The data collected will be captured and subsequently analysed using the Statistical Package for 
Social Sciences (SPSS version 24). Descriptive statistics such as frequencies, percentages, 
means, medians, standard deviations and interquartile ranges will be used to summarize results. 
The CEA levels will be categorized to indicate whether they are elevated or not and further 
cross-tabulated with stage of cancer.  The results will be presented in tables and graphically 
using bar graphs. 
 
13. SELECTION BIAS 
All patients who present with incisional hernia during the above specified study period may not 
be covered. 
 
14. DATA ANALYSIS TECHNIQUES 
Descriptive data analysis will be conducted using the Microsoft Excel generated spreadsheet.  
 
15. LIMITATIONS TO THE STUDY 
All patient’s medical records may not be found, particularly if index abdominal surgery was 
done at other hospitals either than Addington hospital. 
 
16. FUNDING 
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No funding is required 
 
17. ETHICAL CONSIDERATIONS 
Informed patient consent was obtained for collection of the samples and use for statistical 
analysis. The exclusive use of recorded data does not affect the clinical outcomes of the patients 
involved. The confidentiality of the patient will be maintained at all times. 
 
18. INSTITUTIONAL ETHICAL REVIEW BOARD 









- 50 - 
  
Appendix 2- DOHET approved journal guidelines for submission of manuscript 
- 51 - 
 
 





- 53 - 
 
 
Appendix 2- Institutional Ethics Approval  ppendix 3- Institutional Ethics Approval  




Appendix 4- Department of Health Approval to conduct the study  
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Appendix 5: Duke’s staging for Colorectal Cancer 
 Dukes A: invasion into but not through the bowel wall  
 Dukes B: invasion through the bowel wall but not involving lymph nodes  
 Dukes C:  involvement of lymph nodes 
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Appendix 6: UICC (Union for International Cancer Control) staging for Colorectal Cancer 
Primary tumor (pT) 
 TX: primary tumor cannot be assessed 
 T0: no evidence of primary tumor 
 Tis: carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no 
extension through muscularis mucosae) 
 T1: tumor invades submucosa (through the muscularis mucosa but not into the 
muscularis propria) 
 T2: tumor invades muscularis propria 
 T3: tumor invades through the muscularis propria into the pericolorectal tissues 
 T4: 
o T4a: tumor invades through the visceral peritoneum (including gross perforation 
of the bowel through tumor and continuous invasion of tumor through areas of 
inflammation to the surface of the visceral peritoneum) 
o T4b: tumor directly invades or adheres to other adjacent organs or structures 
 
Regional lymph nodes (pN) 
 NX: regional lymph nodes cannot be assessed 
 N0: no regional lymph node metastasis 
 N1: metastasis in 1 - 3 regional lymph nodes 
o N1a: metastasis in 1 regional lymph node 
o N1b: metastasis in 2 - 3 regional lymph nodes 
o N1c: no regional lymph nodes are positive but there are tumor deposits in the 
subserosa, mesentery or nonperitonealized pericolic or perirectal / mesorectal 
tissues 
 N2: metastasis in 4 or more regional lymph nodes 
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o N2a: metastasis in 4 - 6 regional lymph nodes 
o N2b: metastasis in 7 or more regional lymph nodes 
 
Distant metastasis (pM) 
 M0: no distant metastasis by imaging; no evidence of tumor in other sites or organs (this 
category is NOT assigned by pathologists) 
 M1: distant metastasis 
o M1a: metastasis confined to 1 organ or site without peritoneal metastasis 
o M1b: metastasis to 2 or more sites or organs is identified without peritoneal 
metastasis 






Stage 0: Tis N0 M0 
Stage I: T1 - T2 N0 M0 
Stage IIA: T3 N0 M0 
Stage IIB: T4a N0 M0 
Stage IIC: T4b N0 M0 
Stage IIIA: T1 - T2 N1 / N1c M0 
 
T1 N2a M0 
Stage IIIB: T3 - T4a N1 / N1c M0 
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T2 - T3 N2a M0 
 
T1 - T2 N2b M0 
Stage IIIC: T4a N2a M0 
 
T3 - T4a N2b M0 
 
T4b N1 - N2 M0 
Stage IVA: any T any N M1a 
Stage IVB: any T any N M1b 
Stage IVC: any T any N M1c 
 
